reason report
bottom line merck op advanc agonist
phase indic confid program
enthusiast data merck present
societi immunotherapi cancer meet last year
though sever import piec data withheld presum
competit reason nudg price target
reflect updat mileston time risk
close thursday aduro announc receipt
mileston payment merck op advanc
combin keytruda pembrolizumab phase
trial first combin cohort new
umbrella master protocol test novel combin
non-smal cell lung cancer nsclc patient previous
treat therapi
share perspect agon last fall link link
blend dcf analysi
multipl revenu
year price history/av daili volume mil
compani inform svb leerink llc research
revenu ep quarterli figur may sum annual total due round
pleas refer page import disclosur price chart analyst certif
outperform rate pt base valu clinical- stage sting
agonist program agonist collabor iga
nephropathi igan cga collabor remain cautious posit
sting agonist depth biolog evid complementar
checkpoint inhibit multipl mechan prime adapt innat
immun system find biolog rational anti-april applic iga
project revenu mont carlo simul rang
outcom part entir industri immuno-oncolog pipelin valuat
price target base blend dcf analysi multipl revenu
agonist collabor igan cga collabor
take account net cash hand overhead
see sever risk sting scope restrict intratumor deliveri
and/or limit abscop effect therapeut window may prove narrow effect
optim failur sting random trial reduc
enthusiasm entir sting class relat class agonist oncolyt
virus and/or system sting may show better signal risk anti-april
igan includ failur atacicept otski slow recruit need long-
term studi see impact surrog biomark
part valuat
svb leerink estim compani report financi
daina graybosch ph certifi view express report accur reflect view part
compens directli relat specif recommend view contain report
rate price target histori inc
leerink initi coverag outperform rate may
creat bluematrix
project revenu mont carlo simul rang outcom part
entir industri immuno-oncolog pipelin valuat price target base blend dcf
analysi multipl revenu agonist collabor igan cga
collabor take account net cash hand overhead
risk valuat
see sever risk sting scope restrict intratumor deliveri and/or limit abscop
effect therapeut window may prove narrow effect optim failur sting
random trial reduc enthusiasm entir sting class relat class agonist
oncolyt virus and/or system sting may show better signal risk anti-april igan includ
failur atacicept otski slow recruit need long-term studi see impact surrog
rate price target histori merck co inc
leerink place market perform rate februari
creat bluematrix
price target base dcf use wacc account net cash assum
valu newco spin-out project revenu gener rang outcom keytruda mrk
io asset deriv mont carlo simul entir io industri pipelin develop path
iter model growth vaccin hiv franchis consensu estim vertic
risk valuat
keytruda-specif risk increment scientif innov io may continu prove difficult initi
burst may fail pursu most-promis add-on therapi bd competitor reli
price reimburs relat risk us legisl affect drug price propos price
model risk commerci pharma keytruda exposur medicar part could make particularli
sensit us health-system reform oncolog model remov practic incent prefer high-volum
high-reb option major leg keytruda competit moat risk reimburs enhanc oversea
re-negoti drug switch routin practic low-cost local altern china could drive
price one keytruda fastest grow market
also face execut risk plan spin-out low-margin asset newco disrupt accret
assum
rate price target histori compani
leerink place outperform rate octob
creat bluematrix
sinc suspend coverag share longer put forth valuat
risk valuat
sinc suspend coverag longer put forth risk valuat
distribut ratings/invest bank servic ib
explan rate
outperform buy expect stock outperform benchmark next month
market perform hold/neutr expect stock perform line benchmark next
under-perform sell expect stock under-perform benchmark next month
degre out-performance under-perform requir warrant outperform under-perform
rate commensur risk profil compani
purpos definit relev benchmark issuer
market capit less billion issuer market
capit billion
